This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Understood. Thank you for being specific about the limits of it.
The thing about appetite effects that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
The C-cell finding in rodent toxicology is a receptor-biology observation with a species-specific interpretation. It is the reason for a specific contraindication rather than a general concern.
Reading it again, the caveat matters more than the finding.
Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ between compounds are usually about potency or receptor selectivity.
I have left out the parts I could not verify.
I have been on both sides of the appetite effects argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
Everything in post #33 holds. The case it does not cover is the one I have.
What I want from this appetite effects thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Narrowing post #37, because the general version has more than one answer.
Nothing in receptor biology tells you what is in the vial, which is worth remembering when a mechanistic thread starts being used to justify a sourcing decision.
Second-hand, so weight it accordingly.
Ghrelin receptor agonism drives growth hormone release in pulses and also increases appetite, which is the effect people most reliably report and least often want.
That is a description of practice, not a recommendation of it.
The honest answer on appetite effects is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
Where I part company with post #40, and it is a narrow parting.
I read the earlier replies on appetite effects twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Adding the measurement that post #42 says would settle it.
Species differences: rodent studies show the same compounds produce effects in rodents that predict human effects reasonably well for semaglutide and tirzepatide. The track record is less clear for novel compounds with less human data.
If that is already documented somewhere, ignore me and link it.
A note on how appetite effects gets discussed rather than on appetite effects itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Understood, and I withdraw the assumption I opened with.
I had written a reply contradicting post #44 and deleted it. Here is what survived.
My position on appetite effects is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
The area postrema sits outside the blood-brain barrier and is where a great deal of the nausea signalling in this class originates. That is why the effect is central and not gastric irritation.
Adding a source would improve this post and I do not have one to hand.
Where a mechanism is proposed to explain an effect, the useful follow-up is what observation would distinguish it from the alternative. Most mechanistic threads here never get asked that.
Post #46 is right about the mechanism and I think understates the practical bit.
Long-term receptor changes: very little is known about what happens to receptor expression, signalling, and downstream effects over years of exposure to these compounds. That is exactly the knowledge gap phase 3 trials exist to fill.
It took me longer than it should have to see that.
Mechanistic plausibility has a poor record of predicting clinical outcomes across this whole field. It is a good reason to run the trial and a bad reason to skip it.
Worth separating appetite effects as a question about the compound from appetite effects as a question about the documentation. They get answered by different people and only one of them is answerable here.
GLP-1 receptor agonism produces its metabolic effects through more than one route: central satiety signalling, delayed gastric emptying, and glucose-dependent insulin secretion. Attributing everything to one of them is where most simplified accounts go wrong.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
I read post #51 twice before replying, because I had assumed the opposite.
Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ between compounds are usually about potency or receptor selectivity.
Adding the caveat now so it does not have to be extracted later.
I would put moderate confidence on the mainstream reading of appetite effects and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
The question underneath appetite effects is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide activates both GLP-1 and GIP with different affinities. The off-target effects are part of the overall pharmacology.
Everything in post #55 holds. The case it does not cover is the one I have.
Central versus peripheral action: GLP-1 agonism works through both central nervous system effects (appetite) and peripheral effects (gastric motility, insulin). The balance is not fully characterised.
I would want the raw data before agreeing with my own summary of it.
Narrowing post #59, because the general version has more than one answer.
GLP-1 receptor signalling: the GLP-1 receptor is expressed on beta cells (insulin secretion), on neurons (appetite and gastric motility), and on myocardium (contractility). Different tissues respond to the same signal in different ways.
One more caveat and then I will stop qualifying: the sample selected itself.